Filing Details

Accession Number:
0001104659-20-139098
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-23 16:15:09
Reporting Period:
2020-12-22
Accepted Time:
2020-12-23 16:15:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1104506 Insmed Inc INSM Pharmaceutical Preparations (2834) 541972729
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1402051 William Lewis 700 Us Highway 202/206
Bridgewater NJ 08807
Chair&chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-12-22 50,000 $3.40 214,787 No 4 M Direct
Common Stock Disposition 2020-12-22 38,367 $36.45 176,420 No 4 S Direct
Common Stock Disposition 2020-12-22 11,633 $36.98 164,787 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-12-22 50,000 $0.00 50,000 $3.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
180,630 2022-09-10 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  2. This is the weighted average sales price representing 38,367 shares sold at prices ranging from $35.83 to $36.82 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  3. This is the weighted average sales price representing 11,633 shares sold at prices ranging from $36.83 to $37.46 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  4. The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.